Routine use of beta-blockers following myocardial infarction: a note of dissent The best treatment for the survivors of myocardial infarction is still uncertain. Two main strategies have been tried. First, investigations such as a predischarge exercise test have been used in an attempt to identify a group of patients at high risk of a subsequent cardiac event"2. Once such patients are identified, therapeutic endeavours can be concentrated on them. The benefit of surgical intervention in such a high-risk group is currently being assessed in the European post-infarction coronary bypass study. The second strategy is to attempt to treat all survivors with a single agent so that any at high risk will thereby receive treatmnent. In this regard there has been much interest in the use of beta-blockers commencing at about the time patients leave hospital, and two studies have shown benefit from their use at this time. The earlier one, from the Norwegian Multicenter Study Group, showed that over a 33-month follow-up period in a group of survivors treated with timolol, the probability of death was reduced by 39.3% when compared with a similar group who received placebo. The later study, the Beta-blocker Heart Attack Trial (BHAT)4, followed a similar protocol but used propranolol as the trial drug. This showed a smaller but nevertheless impressive reduction in mortality, 26%, over the same follow-up period. This group went further than the former as they recommended the use of propranolol for 'at least three years in patients with no contraindications to beta-blockade who have had a recent MI'.
Although impressive in terms of reduction in mortality, a different picture emerges if survival is considered. One-year survival for those treated with timolol was 93.2% and with propranolol 96.3%; the corresponding survival rates for those receiving placebo were 89.3% and 94%. Thus the average oneyear survival for those treated with beta-blockade was 94.8% whereas in those receiving placebo it was 91.7%, a difference of only 3%. In other words, even without active treatment, about 92 of every 100 patients discharged from hospital following myocardial infarction would be alive one year later. Treating all 100 with a beta-blocker would only increase survival by 3.
If a policy of routine treatment of patients is to be recommended, it is worth considering the likely effect on national figures. Epidemiological data are provided by the government-funded Office of Population Censuses and Surveys. One of their studies is the Hospital In-patient Enquiry, which is a 1 in 10 sample of hospital discharges and deaths in NHS acute hospitals in England and Wales. Patients are classifid by diagnosis. The sum of discharges and deaths gives the number of admissions. In 1981 there were 100 360 hospital admissions for acute myocardial infarction; 75 240 were discharged5'6. This gives a disappointingly high overall hospital mortality of 25%. Extrapolating from the results of the two studies discussed above3 4, some 69 000 of these patients would be expected to be alive one year later if none was treated with beta-blockers whereas if all were so treated about 71300 would be alivea potential saving of 2300 lives. This compares with a total national infarction mortality of 107 0007 and suggests a potential reduction of total national infarction mortality of 2.1%.
When the cost of routine treatment is considered, we find that the cost of one year's treatment for one patient with timolol (Blockadren 10 mg twice daily) is £77.53 whereas using propranolol (Inderal 80mg three times daily) it is £48.188. For all 75 240 patients the cost would be £5 833 060 using timolol, or £3 625 060 if propranolol were used. These costs are based on the basic prices in Mims and do not take into account any discounts; on the other hand, they do not include dispensing costs.
Unfortunately the potential saving of life is likely to be less. Many patients have contraindications to beta-blockers that are readily apparent, the main ones being respiratory diseases such as chronic bronchitis or asthma and left ventricular failure. Both the studies quoted3'4 estimated that 18% of survivors of myocardial infarction had contraindications to beta-blockade.
Assuming that the risk of death in patients with and without a contraindication to beta-blockade is the same, then at best 1900 lives might be saved in the first year if all suitable survivors of infarction were treated with beta-blockers. The number would almost certainly be reduced by patients developing side effects requiring withdrawal of the beta-blockers. In the real world outside the confines of a clinical trial, however, it is possible that a number of patients with abnormalities such as first degree atrioventricular block or who are on the brink ofcardiac failure would be started on beta-blockers. This might well result in an increase in the morbidity and mortality from complete atrioventricular block -and left ventricular failure. Further, it is worrying that the routine use of beta-blockers might niask the development of postinfarction angina, which could indicate the-need for 0141-0768/87/ 070402-02/$02.00/0 i 1987 The Royal Society of Medicine consideration of coronary angiography and bypass surgery.
What does all this mean for the general practitioner? From the national figures a group practice with 6000 patients would expect to admit to hospital about 12 patients a year with a myocardial infarction. Three would die there, so 9 would leave hospital. Only one would die in the next year. Over a period of 11 years the practice might, at best, have saved the lives of 3 patients if all the survivors were treated with beta-blockers for the year following hospital discharge.
It is difficult to gauge the current attitudes of general practitioners, though some doubts have been expressed9. Amongst British consultant cardiologists there does seem to have been a positive response: a random survey of 100 consultant cardiologists, ofwhom 83 answered questionnaires, indicated that 60 (72%) used beta-blockers prophylactically. However, half of these only gave them to patients they felt were at 'high risk of death or reinfarction', whilst the remainder prescribed them to all suitable survivorsl'.
In contrast, cessation of smoking following myocardial infarction reduced the prevalence of angina at one year from 32.2% to 19.5% in males under the age of 60 years. Unfortunately after six years this benefit was lost". The effects on prognosis have been more impressive. Over a five-year follow up period, considering the smoking habits of survivors three months after infarction, there was 87% survival (13% mortality) amongst ex-smokers compared with only 72% survival (28% mortality) amongst those who had continued to smoke. For comparison with the foregoing trials of beta-blockers, at 3 years survival was 90% in ex-smokers compared with 85% in smokers'2.
In conclusion, if beta-blockers were routinely used in England and Wales in the first year after myocardial infarction, 61700 patients could be treated at a cost of about £4 350 000. About 1900 lives might be saved. This would reduce total mortality from myocardial infarction by less than 2%. For a general practitioner working in a three-partner practice this would mean treating about 33 patients and a life saved every 11 years. Persuading survivors of infarction to stop smoking might well be at least equally effective in the long term, at lower cost and with less side effects.
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Perlite and other 'nuisance' dusts It is the practice of national and international agencies concerned with the health and safety of workers to classify certain dusts as dangerous and to lay down safety limits for the levels of exposure which are permitted without respiratory protection. Crystalline quartz was one of the first materials to be recognized as dangerous and the internationally agreed limit is 0.1 mg/m3 for particles less than 5 microns in diameter or 0.3 mg/m3 for total dust. The limits for asbestos are of course much lower because of the risk of lung cancer and mesothelioma. Other non-fibrous mineral dusts are for the most part classified as 'nuisance' dusts, with limits of 5 mg/m3 respirable and 10 mg/m3 total. These limits are regarded by some people as meeting a social acceptability standard rather than a health and safety one. When such a dust contains more than 1% quartz, either because the rock from which it is derived contains quartz as one of its constituents or because the deposit is contaminated with quartz from adjacent strata, then safety standards are laid down using a formula based on the percentage of quartz in the dust.
This policy has led to the concept that nuisance dusts are completely safe unless they contain quartz or one of the fibrous minerals. The public have come to mistrust this sort of official 'line', having been assured ofthe efficacy ofsafety regulations regarding materials like asbestos only to be told a few years later that incurable diseases like mesothelioma could still occur at levels of exposure well within the 0141-0768/87/ 070403-02/$02.00/0 o 1987 The Royal Society of Medicine
